NASDAQ:VCYT Veracyte (VCYT) Stock Price, News & Analysis $26.72 -1.25 (-4.47%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$27.65 +0.93 (+3.50%) As of 05/28/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Veracyte Stock (NASDAQ:VCYT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Veracyte alerts:Sign Up Key Stats Today's Range$26.69▼$27.9750-Day Range$26.72▼$33.6952-Week Range$19.73▼$47.32Volume1.07 million shsAverage Volume896,149 shsMarket Capitalization$2.09 billionP/E RatioN/ADividend YieldN/APrice Target$40.90Consensus RatingModerate Buy Company OverviewVeracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.Read More… Veracyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreVCYT MarketRank™: Veracyte scored higher than 88% of companies evaluated by MarketBeat, and ranked 192nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingVeracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageVeracyte has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Veracyte's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth5.88% Earnings GrowthEarnings for Veracyte are expected to grow by 5.88% in the coming year, from $0.68 to $0.72 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is -178.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is -178.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Veracyte's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.81% of the float of Veracyte has been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Veracyte has recently decreased by 6.46%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.08 Percentage of Shares Shorted6.81% of the float of Veracyte has been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Veracyte has recently decreased by 6.46%, indicating that investor sentiment is improving significantly. News and Social Media3.5 / 5News Sentiment1.26 News SentimentVeracyte has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Veracyte this week, compared to 7 articles on an average week.MarketBeat Follows1 people have added Veracyte to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.40% of the stock of Veracyte is held by insiders.Read more about Veracyte's insider trading history. Receive VCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter. Email Address VCYT Stock News HeadlinesVeracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCOMay 29 at 12:57 AM | insidermonkey.comVeracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer ResearchMay 28 at 4:18 PM | businesswire.comThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 29, 2025 | Timothy Sykes (Ad)Veracyte: Upgrading To NeutralMay 26 at 10:32 AM | seekingalpha.comComparing Veracyte (NASDAQ:VCYT) and Grail (NASDAQ:GRAL)May 22, 2025 | americanbankingnews.comVeracyte to Participate in Upcoming Investor ConferencesMay 20, 2025 | businesswire.comBreaking Down Veracyte: 7 Analysts Share Their ViewsMay 10, 2025 | nasdaq.comVeracyte, Inc. Just Recorded A 260% EPS Beat: Here's What Analysts Are Forecasting NextMay 10, 2025 | finance.yahoo.comSee More Headlines VCYT Stock Analysis - Frequently Asked Questions How have VCYT shares performed this year? Veracyte's stock was trading at $39.60 at the beginning of the year. Since then, VCYT stock has decreased by 32.5% and is now trading at $26.72. View the best growth stocks for 2025 here. How were Veracyte's earnings last quarter? Veracyte, Inc. (NASDAQ:VCYT) posted its quarterly earnings results on Monday, February, 24th. The biotechnology company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.07. The biotechnology company earned $118.63 million during the quarter, compared to analysts' expectations of $110.73 million. Veracyte had a positive trailing twelve-month return on equity of 3.02% and a negative net margin of 2.18%. Read the conference call transcript. Does Veracyte have any subsidiaries? Veracyte subsidiaries include HalioDx Inc., Decipher Biosciences Inc., Allegro Diagnostics, Decipher Corp., Delight Merger Sub II LLC, Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS. Who are Veracyte's major shareholders? Top institutional investors of Veracyte include Vanguard Group Inc. (10.55%), ARK Investment Management LLC (5.03%), Wellington Management Group LLP (4.92%) and Sumitomo Mitsui Trust Group Inc. (2.90%). Insiders that own company stock include Rebecca Chambers, John Leite, Giulia C Kennedy, Bonnie H Anderson, Jonathan Wygant, Jonathan Wygant, Evan/ Fa Jones, John L Bishop, Jens Holstein, Muna Bhanji and Karin Eastham. View institutional ownership trends. How do I buy shares of Veracyte? Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Veracyte investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings2/24/2025Today5/28/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:VCYT CIK1384101 Webwww.veracyte.com Phone(650) 243-6300Fax650-243-6301Employees790Year Founded2006Price Target and Rating Average Stock Price Target$40.90 High Stock Price Target$50.00 Low Stock Price Target$28.00 Potential Upside/Downside+53.1%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$0.41 Trailing P/E RatioN/A Forward P/E Ratio39.29 P/E GrowthN/ANet Income-$74.40 million Net Margins-2.18% Pretax Margin-1.92% Return on Equity3.02% Return on Assets2.80% Debt Debt-to-Equity RatioN/A Current Ratio5.08 Quick Ratio4.79 Sales & Book Value Annual Sales$463.39 million Price / Sales4.52 Cash Flow$0.06 per share Price / Cash Flow442.29 Book Value$14.30 per share Price / Book1.87Miscellaneous Outstanding Shares78,315,000Free Float76,493,000Market Cap$2.09 billion OptionableOptionable Beta2.14 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:VCYT) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.